Monday, February 05, 2007 1:24:08 PM
URANIUM PROPERTY, QUEBEC
February 5, 2007
TSX-V Symbol: URC
Vancouver, B.C. – Uracan Resources Ltd. (the “Company”) is pleased to announce that it has commenced drilling on its North Shore Uranium Property in Quebec.
The 12,000 meter drilling program will test at least four separate first order uranium anomalies and occurrences (Lac Petit - Double S, Lac Turgeon, Lac Tanguay and Baie Johann Beetz) outlined by airborne geophysics and surface exploration work carried out during 2006 (refer to the news release dated January 17, 2007). Approximately 16 km2 of the 900 km2 North Shore Property will be tested during this drill program. Additional targets remain to be tested throughout the remainder of the property.
Drill core will be logged and sampled in the field, with the samples submitted to ALS-Chemex in Val-d’Or for analysis. A rigorous QAQC program will be carried out as part of the sampling protocol to ensure the precision and accuracy of results.
Uracan Resources Ltd. is a publicly-listed uranium exploration company, exploring for shallow, bulk tonnage style of uranium mineralization in Canada. Uracan is led by a team of proven exploration and mine entrepreneurs and mine-builders. For further information please go to www.uracan.ca
The information in this news release has been prepared and reviewed by Marc Simpson, P. Geo., the Company’s Qualified Person under National Instrument 43-101 standards.
For further information please contact:
Investor Relations,Vanguard Shareholder Solutions
Tel:(604) 608-0824 or 1 866-898-0824
Email: ir@vanguardsolutions.ca
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. The foregoing information may contain forward-looking statements relating to the future performance of Uracan Resources Ltd. Forward-looking statements, specifically those concerning future performance, are subject to certain risks and uncertainties, and actual results may differ materially. These risks and uncertainties are detailed from time to time in the Company’s filings with the appropriate securities commissions.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM